# Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

> **NCT02274415** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 116 (actual)

## Conditions studied

- Invasive Pneumococcal Infections
- Sickle Cells Disease

## Interventions

- **BIOLOGICAL:** Vaccination with the combined vaccine (Prevenar13 ®)
- **BIOLOGICAL:** Vaccination with the polysaccharide vaccine (Pneumo 23 ®)

## Key facts

- **NCT ID:** NCT02274415
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-16
- **Primary completion:** 2017-09-18
- **Final completion:** 2019-04-10
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2022-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274415, "Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02274415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*